Sign in Subscribe

preclinical

A collection of 65 issues

Propionate enhances CD8+ T-cell infiltration and immunotherapy response in preclinical models

Skip to content The CRC Digest ◇ RESEARCH Propionate enhances CD8+ T-cell infiltration and immunotherapy response in preclinical models A study using syngeneic MSI-H and MSS murine colorectal cancer models found that propionate, a short-chain fatty acid produced by gut microbiota, promoted CD8+ T-cell infiltration and enhanced efficacy when combined with

Gut Microbial Metabolites Screened for Role in Modulating PD-1/SHP-2 Interaction in MSS CRC

Skip to content The CRC Digest Gut Microbial Metabolites Screened for Role in Modulating PD-1/SHP-2 Interaction in MSS CRC Researchers established a screening system to identify gut microbiome-derived metabolites that may regulate anti-tumor immunity in microsatellite-stable colorectal cancer by modulating the PD-1/SHP-2 signaling pathway. (Journal for ImmunoTherapy of

Portable urine-based biosensor developed for colorectal cancer detection in low-resource settings

Skip to content The CRC Digest ▪ SCREENING Portable urine-based biosensor developed for colorectal cancer detection in low-resource settings Researchers present a low-cost, semi-automated point-of-care platform that measures urinary metabolite biomarkers for CRC triage where colonoscopy access is limited. (Biosensors) This content is informational only and does not constitute medical advice.

RNF43 mutation linked to immune evasion in MSI-high colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH RNF43 mutation linked to immune evasion in MSI-high colorectal cancer The RNF43 p.G659fs mutation, found in 8% of colorectal cancers and enriched in MSI-H tumors, promotes natural killer cell dysfunction through PI3K/AKT/mTOR signaling and HLA-E up-regulation. (Sci Adv) This content

Gut bacterium Eggerthella lenta linked to liver metastasis via vascular barrier disruption

Skip to content The CRC Digest ◇ RESEARCH Gut bacterium Eggerthella lenta linked to liver metastasis via vascular barrier disruption Multi-omics analysis of two cohorts comprising 20 healthy controls, 82 non-metastatic CRC patients, and 65 patients with liver or lung metastases found that those with CRC liver metastasis had impaired gut

PADI-Dependent Mitochondrial Adaptation Drives Resistance to KRAS Inhibitors

Skip to content The CRC Digest ◇ RESEARCH PADI-Dependent Mitochondrial Adaptation Drives Resistance to KRAS Inhibitors Researchers identified PADI1 and PADI3 as negative prognostic markers in KRAS-mutant colorectal and pancreatic cancers; pharmacological inhibition of PADIs synergizes with KRAS inhibitors in preclinical models and restores sensitivity in resistant cells. (Cell Rep) This

Study identifies FAIM2 pathway in cancer-associated fibroblasts linked to immune resistance in MSS colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Study identifies FAIM2 pathway in cancer-associated fibroblasts linked to immune resistance in MSS colorectal cancer Researchers identified Fas apoptotic inhibitory molecule 2 (FAIM2) as a stromal regulator downregulated in microsatellite-stable colorectal cancer, where it inversely correlates with collagen production in cancer-associated fibroblasts and

KRAS Mutations Shape Immunosuppressive Tumor Environment

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutations Shape Immunosuppressive Tumor Environment A review describes how KRAS mutations—present in approximately 52% of colorectal cancers—actively create an immunosuppressive tumor microenvironment, presenting a major barrier to both targeted therapy and immunotherapy. (Frontiers in Oncology) This content is informational only

KRAS Mutation Enriches Gut Bacteria Linked to Tumor Growth

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutation Enriches Gut Bacteria Linked to Tumor Growth A study in KRAS-mutant CRC patients and mice found that KRAS reshapes the microbial community, enriching Bacteroides acidifaciens, which predicts poor prognosis and promotes malignant phenotypes in KRAS-mutant tumors. (Cell Host & Microbe) This

Calcitriol Modulates Age-Dependent Drug Response in Patient-Derived Colorectal Organoids

Skip to content The CRC Digest Calcitriol Modulates Age-Dependent Drug Response in Patient-Derived Colorectal Organoids Researchers used paired patient-derived normal and tumor colorectal organoids to investigate how calcitriol (the active vitamin D metabolite) modulates chemotherapy response. Dose-response analyses revealed marked interpatient variability, with SN38 being more potent than 5-fluorouracil and